Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2013, Pages

  Darbà, Josep ^a   Kaskens, Lisette ^b   Sánchez de la Rosa, Rainel ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BCN Health Economics and Outcomes Research SL   (Spain)

^c TEVA PHARMACEUTICALS   (Israel)

Author keywords

Breakthrough pain; Cancer; Costs; Economic analysis; Rapid onset opioids

Indexed keywords

FENTANYL;

ANXIETY DISORDER; ARTICLE; BREAKTHROUGH CANCER PAIN; BREAKTHROUGH PAIN; BUDGET; BUDGET IMPACT ANALYSIS; CANCER PAIN; CONSTIPATION; CONTROLLED STUDY; COST CONTROL; DIARRHEA; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; DYSGEUSIA; ECONOMIC EVALUATION; HEADACHE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INTOXICATION; NAUSEA AND VOMITING; OPIOID INTOXICATION; PREVALENCE; PRURITUS; SENSITIVITY ANALYSIS; SOMNOLENCE; SPAIN; TABLET;

EID: 84890467428     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S52273     Document Type: Article

References (45)

1. Mercadante S. Cancer pain. Curr Opin Support Palliat Care. 2013;7: 139-143.
2. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59:850-856.
3. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-338.
4. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001;21: 144-150.
5. Portenoy RK, Hagen NA. Breakthrough pain: defnition, prevalence and characteristics. Pain. 1990;41:273-281.
6. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81:129-34.
7. Mercadante S, Radbruch L, Caraceni A, et al; Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832-839.
8. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181-190.
9. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med. 2004;18:177-183.
10. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain. Part 1: prevalence and characteristics. J Opioid Manag. 2010;6: 97-108.
11. Mercadante S, Costanzo B V, Fusco F, et al. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage. 2009;38:554-560.
12. Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage. 2010;40:183-190.
13. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7:583-591.
14. Dickman A. Basics of managing breakthrough cancer pain. Pharm J. 2009;283:e213-e216.
15. Fortner B V, Okon TA, Portenoy RK. A survey of pain-related hospitaliza-tions, emergency department visits, and physician offce visits by cancer patients with and without breakthrough pain. J Pain. 2002;3:38-44.
16. Fortner B V, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25:9-18.
17. Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs. 2012;26:509-535.
18. Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med. 2010;25:516-524.
19. Zeppetella G. Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care. 2009;18:331-337.
20. McWilliams K, Fallon M. Fast-acting fentanyl preparations and pain management. QJM. 2013;106:887-890.
21. Jandhyala R, Fullarton JR, Bennett MI. Effcacy of rapid-onset oral fentanyl formulations vs oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. February 1, 2013. [Epub ahead of print.]
22. Di Palma M, Poulain P, Pichard E. [What's new in the treatment of cancer pain?]. Bull Cancer. 2004;91:95-98. French.
23. Mercadante M. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805-2815.
24. IMS Health. National sales data July 2011-January 2012 for rapid onset opioids, oral morphine and oxycodone for Spain. Data on file.
25. International Association for Cancer Research. GLOBCAN cancer incidence, mortality and prevalence worldwide in 2008. Available from: http://globocan.iarc.fr/summary_table_site_prev.asp?selection=280&title=All+cancers+excl.+non. Accessed May 8, 2013.
26. Instituto Nacional de Estadístico. [National institure for statistics. Projections for the population on the short term.] Proyecciones de población a corto plazo. 2011-2021. Available from: http://www.ine.es/jaxi/menu.do?type=pcaxis&path=%2Ft20%2Fp269%2F2011-2021&fle=pcaxis&L=. Accessed October 12, 2012.
27. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002;24:45-52.
28. Fallon M, Reale C, Davies A, et al. Fentanyl nasal spray study. Effcacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224-231.
29. Agencia de Medicamentos y Productos Sanitarios Española. Ficha técnica de Actiq®. Available from: http://www.aemps.gob.es/cima/fchasTecnicas.do?metodo=buscar. Accessed June 25, 2013.
30. Agencia de Medicamentos y Productos Sanitarios Española. Ficha técnica de Abstral®. Available from: http://www.aemps.gob.es/cima/fchasTecnicas.do?metodo=buscar. Accessed June 25, 2013.
31. Agencia de Medicamentos y Productos Sanitarios Española. Ficha técnica de PecFent®. Available from: http://www.aemps.gob.es/cima/fchasTecnicas.do?metodo=buscar. Accessed June 25, 2013.
32. Agencia de Medicamentos y Productos Sanitarios Española. Ficha técnica de Instanyl®. Available from: http://www.aemps.gob.es/cima/fchasTecnicas.do?metodo=buscar. Accessed June 25, 2013.
33. Agencia de Medicamentos y Productos Sanitarios Española. Ficha técnica de Effentora®. Available from: http://www.aemps.gob.es/cima/fchasTecnicas.do?metodo=buscar. Accessed June 25, 2013.
34. Consejo General de Colegios Ofciales de Farmacéuticos. BOT plus web. 2012. Available from: https://botplusweb.portalfarma.com/. Accessed May 8, 2013.
35. Real Decreto-Ley 8/2010, May 20th where extraordinary measures were adopted for public defcit reduction.
36. Davis M P. Recent development in therapeutics for breakthrough pain. Expert Rev Neurother. 2010;10:757-773.
37. Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage. 2008;35:406-411.
38. Ferrell BR, Juarez G, Borneman T. Use of routine and breakthrough analgesia in home care. Oncol Nurs Forum. 1999;26:1655-1661.
39. Ramos Gracia M, Catala Hortelano L, Sala Langa MJ, Gómez Sánchez D, Conejero Morant MA, Saneugenio Gregori J. [Accidental poisoning by intranasal fentanyl.] An Pediatr (Barc). May 15, 2013. [Epub ahead of print.] Spanish.
40. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Effcacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037-1045.
41. Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen J P. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011;14: 274-281.
42. Diari Ofcial de la Generalitat de Catalunya (DOGC) Núm. 5325 - 24.2.2009. Available at: http://www20.gencat.cat/portal/site/portaldogc. Accessed June, 2013.
43. Diari Ofcial de la Generalitat de Catalunya (DOGC) Núm. 5907 - 27.6.2011. Available at: http://www20.gencat.cat/portal/site/portaldogc. Accessed June, 2013.
44. Diario Ofcial de Galicia. (DOG) Núm. 213 Martes, 8 de noviembre de 2011 Pág. 32557. Available at: http://www.xunta.es/diario-ofcial-galicia/8. Accessed June, 2013.
45. Boletin Ofcial de Cantabria. (DOC) Núm. 85 Jueves, 5 de mayo de 2011. Pág. 15393. Available at: http://boc.cantabria.es/boces/. Accessed June, 2013.